The United Kingdom and the United States have reached a key trade agreement that will ensure no duties on British pharmaceutical products entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the National Health Service (NHS). This move secures that duties on these crucial products will stay at zero for a period of 36 months.
This agreement follows earlier threats to dramatically increase tariffs on branded drug imports, with potential rates discussed reaching one hundred percent.
"This deal between the UK strengthens the international landscape for innovative medicines and brings long-overdue equity to transatlantic drug exports," a release noted.
Commercial Importance
Drugs represent one of the Britain's largest exports to the US, which is easily the largest destination for large British pharmaceutical firms.
Export figures show that in the 12 months to the end of last September, the UK exported medicines worth billions to the US. This figure accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a government official remarked.
Specific British Pledges
The deal involves several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise overall public funding on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be capped at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The deal follows a ongoing row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
This friction were intensified by assertions that US consumers were paying a premium for the identical medicines than consumers in the other developed nations.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
